Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated